文献速递心脑血管急症重症综合管理与镇静镇痛

脑卒中患者中神经影像衰弱标志物对年龄与取栓结局的中介作用

Mediation of Age and Thrombectomy Outcome by Neuroimaging Markers of Frailty in Patients With Stroke.
PubMed 文献 · JAMA Netw Open · 2024-01-02
一句话结论ESCAPE-NA1二次分析显示,年龄与90天结局的关联大部分由神经影像衰弱(脑萎缩、小血管病)中介,而非年龄本身。

本研究为ESCAPE-NA1随机临床试验的事后队列分析,纳入8国48家医院1105例接受血管内取栓的急性缺血性卒中患者,其中1102例有可解读的基线影像。采用结构方程模型,将脑萎缩(皮质或皮质下)、白质病变(脑室旁或深部)、腔隙灶及慢性梗死灶数目作为潜变量中介,评估其对年龄与90天功能结局关联的中介比例。结果显示,神经影像衰弱中介了年龄对90天结局总效应的85.1%(β系数0.04/年,95%CI 0.02-0.06/年,P<.001);联合临床衰弱特征后,间接通路中介了几乎100%的总效应(β系数0.07/年,95%CI 0.03-0.10/年,P=.001)。作者认为,预测卒中后结局时应重视脑萎缩和小血管病等特征,而非仅依据实际年龄。

要点

  • 在1102例接受EVT的卒中患者中,神经影像衰弱中介了年龄对90天结局总效应的85.1%(β系数0.04/年,95%CI 0.02-0.06/年,P<.001)。
  • 联合临床衰弱特征后,间接通路中介了几乎100%的年龄效应(β系数0.07/年,95%CI 0.03-0.10/年,P=.001)。
  • 神经影像衰弱标志物包括脑萎缩(皮质或皮质下)、白质病变(脑室旁或深部)、腔隙灶数目和慢性梗死灶。
  • 作者认为,预测卒中后结局时应重视脑萎缩和小血管病等特征,而非仅依据实际年龄。

适用人群与场景

  • 接受血管内取栓(EVT)的急性缺血性卒中患者,来自ESCAPE-NA1试验48家医院、8个国家,2017年3月1日至2019年8月12日入组。
  • 纳入标准为在12小时治疗窗内接受EVT并随机接受静脉 nerinetide 者;排除标准为基线影像无法解读者(1105例中3例排除,最终分析1102例)。

研究设计与关键结果

  • 研究设计:ESCAPE-NA1随机临床试验的事后队列分析,共纳入1105例,其中1102例(中位年龄71岁,IQR 61-80岁;554例[50.3%]男性)有可解读的基线影像。
  • 干预与对照:所有患者接受EVT,随机接受静脉 nerinetide(2.6 mg/kg体重)及必要时阿替普酶治疗 vs 最佳药物治疗;549例(49.8%)接受静脉 nerinetide 治疗。
  • 主要终点:神经影像衰弱中介年龄对90天结局总效应的85.1%(β系数0.04/年,95%CI 0.02-0.06/年,P<.001)。
  • 联合中介分析:纳入临床衰弱特征与神经影像标志物(总衰弱)后,间接通路中介了几乎100%的总效应(β系数0.07/年,95%CI 0.03-0.10/年,P=.001)。
  • 神经影像标志物包括脑萎缩(皮质或皮质下)、白质病变(脑室旁或深部)、腔隙灶数目及慢性梗死灶数目。

证据类型、等级与局限

  • 证据类型:随机临床试验(ESCAPE-NA1)的事后队列分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,预测卒中后结局时应重视脑萎缩和小血管病等特征,而非仅依据实际年龄。
  • 作者提出,未来试验可纳入此类衰弱特征以进行随机分层或改善结局分析中的调整。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Age is a leading predictor of poor outcomes after brain injuries like stroke. The extent to which age is associated with preexisting burdens of brain changes, visible on neuroimaging but rarely considered in acute decision-making or trials, is unknown.

OBJECTIVES: To explore the mediation of age on functional outcome by neuroimaging markers of frailty (hereinafter neuroimaging frailty) in patients with acute ischemic stroke receiving endovascular thrombectomy (EVT).

DESIGN, SETTING, AND PARTICIPANTS: This cohort study was a post hoc analysis of the Safety and Efficacy of Nerinetide (NA-1) in Subjects Undergoing Endovascular Thrombectomy for Stroke (ESCAPE-NA1) randomized clinical trial, which investigated intravenous (IV) nerinetide in patients who underwent EVT within a 12-hour treatment window. Patients from 48 acute care hospitals in 8 countries (Canada, US, Germany, Korea, Australia, Ireland, UK, and Sweden) were enrolled between March 1, 2017, and August 12, 2019. Markers of brain frailty (brain atrophy [subcortical or cortical], white matter disease [periventricular or deep], and the number of lacunes and chronic infarctions) were retrospectively assessed while reviewers were blinded to other imaging (eg, computed tomography angiography, computed tomography perfusion) or outcome variables. All analyses were done between December 1, 2022, and January 31, 2023.

EXPOSURES: All patients received EVT and were randomized to IV nerinetide (2.6 mg/kg of body weight) and alteplase (if indicated) treatment vs best medical management.

MAIN OUTCOME AND MEASURES: The primary outcome was the proportion of the total effect of age on 90-day outcome, mediated by neuroimaging frailty. A combined mediation was also examined by clinical features associated with frailty and neuroimaging markers (total frailty). Structural equation modeling was used to create latent variables as potential mediators, adjusting for baseline, early ischemic changes; stroke severity; onset-to-puncture time; nerinetide treatment; and alteplase treatment.

RESULTS: Among a total of 1105 patients enrolled in the study, 1102 (median age, 71 years [IQR, 61-80 years]; 554 [50.3%] male) had interpretable imaging at baseline. Of these participants, 549 (49.8%) were treated with IV nerinetide. The indirect effect of age on 90-day outcome, mediated by neuroimaging frailty, was associated with 85.1% of the total effect (β coefficient, 0.04 per year [95% CI, 0.02-0.06 per year]; P < .001). When including both frailty constructs, the indirect pathway was associated with essentially 100% of the total effect (β coefficient, 0.07 per year [95% CI, 0.03-0.10 per year]; P = .001).

CONCLUSIONS AND RELEVANCE: In this cohort study, a secondary analysis of the ESCAPE-NA1 trial, most of the association between age and 90-day outcome was mediated by neuroimaging frailty, underscoring the importance of features like brain atrophy and small vessel disease, as opposed to chronological age alone, in predicting poststroke outcomes. Future trials could include such frailty features to stratify randomization or improve adjustment in outcome analyses.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Benali F, Singh N, Fladt J, et al. Mediation of Age and Thrombectomy Outcome by Neuroimaging Markers of Frailty in Patients With Stroke. JAMA Netw Open. 2024. PMID: 38165676. doi:10.1001/jamanetworkopen.2023.49628

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。